TA263 Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer: appendix A - matrix of stakeholders
|
TA263 Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer: appendix A - matrix of stakeholders
29 June 2015 (97.59 Kb 28 sec) |
This page was last updated: 25 June 2015